乾癬治療薬市場：分子、投与経路、剤形、作用機序別-2023～2030年の世界予測

乾癬治療薬の世界市場は、2023年に216億2,000万米ドル、CAGR 9.75%で大きく成長し、2030年には415億5,000万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の乾癬治療薬市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.乾癬治療薬の世界市場規模および予測は？

2.予測期間中、世界の乾癬治療薬市場を形成するCOVID-19の阻害要因と影響は？

3.乾癬治療薬の世界市場において予測期間中に投資すべき製品/セグメント/用途/分野は？

4.乾癬治療薬の世界市場における競争戦略は？

5.乾癬治療薬の世界市場における技術動向と規制の枠組みは？

6.乾癬治療薬の世界市場における主要ベンダーの市場シェアは？

7.乾癬治療薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で高齢者人口が増加
    • 尋常性乾癬および乾癬性関節炎の発生率の増加
    • 治療法に対する有利な償還ポリシー
  • 抑制要因
    • 高額な治療費
  • 機会
    • 生物学的製剤の処方量と承認の増加
    • 新しい生物製剤および新規パイプライン医薬品の新たな開発
  • 課題
    • 薬による健康リスクの可能性
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 乾癬治療薬市場：分子別

• イントロダクション
• 生物製剤
• 低分子

第7章 乾癬治療薬市場：投与経路別

• イントロダクション
• 経口
• 非経口
• 局所

第8章 乾癬治療薬市場：剤形別

• イントロダクション
• 液体
• 半固体
• 固体

第9章 乾癬治療薬市場：作用機序別

• イントロダクション
• ILブロッカー
• PDE4阻害剤
• TNF阻害剤

第10章 南北アメリカの乾癬治療薬市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の乾癬治療薬市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの乾癬治療薬市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別

第14章 掲載企業一覧

第15章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. PSORIASIS THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. PSORIASIS THERAPEUTICS MARKET SIZE, 2022 VS 2030
• FIGURE 3. PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2022 VS 2030 (%)
• FIGURE 5. PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
• FIGURE 6. PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2022 VS 2030 (%)
• FIGURE 7. PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2022 VS 2030 (%)
• FIGURE 8. PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 9. PSORIASIS THERAPEUTICS MARKET DYNAMICS
• FIGURE 10. PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 18. PSORIASIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 19. PSORIASIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. PSORIASIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 5. PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 8. PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. PSORIASIS THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 12. PSORIASIS THERAPEUTICS MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. PSORIASIS THERAPEUTICS MARKET SIZE, BY SEMI-SOLID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. PSORIASIS THERAPEUTICS MARKET SIZE, BY SOLID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 16. PSORIASIS THERAPEUTICS MARKET SIZE, BY IL BLOCKER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 32. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 33. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 34. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 35. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 50. AUSTRALIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 51. AUSTRALIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 54. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 55. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 57. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 58. INDIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 59. INDIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 60. INDIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 61. INDIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 62. INDONESIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 63. INDONESIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. INDONESIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 66. JAPAN PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 67. JAPAN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. JAPAN PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 70. MALAYSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 71. MALAYSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. MALAYSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 74. PHILIPPINES PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 75. PHILIPPINES PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. PHILIPPINES PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 78. SINGAPORE PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 79. SINGAPORE PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 80. SINGAPORE PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 82. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 83. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 86. TAIWAN PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 87. TAIWAN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. TAIWAN PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 90. THAILAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 91. THAILAND PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 92. THAILAND PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 94. VIETNAM PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 95. VIETNAM PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. VIETNAM PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 98. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 99. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 103. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 104. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 105. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 107. EGYPT PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 108. EGYPT PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. EGYPT PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 111. FINLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 112. FINLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. FINLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 115. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 116. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 117. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 119. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 120. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 121. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 123. ISRAEL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 124. ISRAEL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. ISRAEL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 127. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 128. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 129. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 130. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 131. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 132. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 133. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 135. NIGERIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 136. NIGERIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 137. NIGERIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 139. NORWAY PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 140. NORWAY PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 141. NORWAY PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 143. POLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 144. POLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. POLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 146. POLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 147. QATAR PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 148. QATAR PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 149. QATAR PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 150. QATAR PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 151. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 152. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 153. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 155. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 156. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 157. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 159. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 160. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 161. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 163. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 164. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 165. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 167. SWEDEN PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 168. SWEDEN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 169. SWEDEN PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 171. SWITZERLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 172. SWITZERLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 173. SWITZERLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 175. TURKEY PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 176. TURKEY PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 177. TURKEY PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 179. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 180. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 181. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 183. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 184. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 185. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 187. PSORIASIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 188. PSORIASIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 189. PSORIASIS THERAPEUTICS MARKET LICENSE & PRICING

The Global Psoriasis Therapeutics Market is forecasted to grow significantly, with a projected USD 21.62 billion in 2023 at a CAGR of 9.75% and expected to reach a staggering USD 41.55 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Psoriasis Therapeutics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Psoriasis Therapeutics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Molecule, market is studied across Biologics and Small Molecules. The Small Molecules is projected to witness significant market share during forecast period.

Based on Route of Administration, market is studied across Oral, Parenteral, and Topical. The Topical is projected to witness significant market share during forecast period.

Based on Dosage Forms, market is studied across Liquid, Semi-Solid, and Solid. The Liquid is projected to witness significant market share during forecast period.

Based on Mechanism of Action, market is studied across IL Blocker, PDE4 Inhibitors, and TNF Inhibitors. The TNF Inhibitors is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Psoriasis Therapeutics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Psoriasis Therapeutics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Psoriasis Therapeutics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Psoriasis Therapeutics Market?

4. What is the competitive strategic window for opportunities in the Global Psoriasis Therapeutics Market?

5. What are the technology trends and regulatory frameworks in the Global Psoriasis Therapeutics Market?

6. What is the market share of the leading vendors in the Global Psoriasis Therapeutics Market?

7. What modes and strategic moves are considered suitable for entering the Global Psoriasis Therapeutics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Psoriasis Therapeutics Market, by Molecule, 2022 vs 2030
• 4.3. Psoriasis Therapeutics Market, by Route of Administration, 2022 vs 2030
• 4.4. Psoriasis Therapeutics Market, by Dosage Forms, 2022 vs 2030
• 4.5. Psoriasis Therapeutics Market, by Mechanism of Action, 2022 vs 2030
• 4.6. Psoriasis Therapeutics Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing elderly population worldwide
    • 5.1.1.2. Increasing incidence of plaque psoriasis and psoriasis arthritis
    • 5.1.1.3. Favorable reimbursement policies for such therapeutics
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of therapeutics
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising prescription volume and approvals of biologic products
    • 5.1.3.2. Emerging development of new biologics and novel pipeline drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Probable health risks due to the medication
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Psoriasis Therapeutics Market, by Molecule

• 6.1. Introduction
• 6.2. Biologics
• 6.3. Small Molecules

7. Psoriasis Therapeutics Market, by Route of Administration

• 7.1. Introduction
• 7.2. Oral
• 7.3. Parenteral
• 7.4. Topical

8. Psoriasis Therapeutics Market, by Dosage Forms

• 8.1. Introduction
• 8.2. Liquid
• 8.3. Semi-Solid
• 8.4. Solid

9. Psoriasis Therapeutics Market, by Mechanism of Action

• 9.1. Introduction
• 9.2. IL Blocker
• 9.3. PDE4 Inhibitors
• 9.4. TNF Inhibitors

10. Americas Psoriasis Therapeutics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Psoriasis Therapeutics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Psoriasis Therapeutics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. FPNV Positioning Matrix
• 13.2. Market Share Analysis, By Key Player
• 13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

• 15.1. Discussion Guide
• 15.2. License & Pricing